Skip to main content
. 2017 Apr 27;8(33):55657–55683. doi: 10.18632/oncotarget.17497

Figure 3.

Figure 3

Forest plots of 15 studies evaluating heterogeneity test of chemotherapy regimens difference (MMC based chemotherapy; L-OHP based chemotherapy; others) in HIPEC procedure (a); The difference of mean year survival rate between CRS+HIPEC group and traditional group for MMC-basic (Mitomycin C, MMC) HIPEC procedure (b), for L-OHP-basic (Oxaliplatin, L-OHP) HIPEC procedure (c); Forest plots of 15 studies evaluating heterogeneity test of the proportion of CC0 difference (d).